Metals and Mining Industry Outlook – Noble Capital Markets Natural Resources Sector Review – Q1 2022

Noble Capital Markets Metals and Mining Newsletter – Q1 2022


Source: Capital IQ as of 03/31/2022

Source: Capital IQ as of 03/31/2022; Company Filings

METALS AND MINING INDUSTRY OUTLOOK

Metals & Mining First Quarter 2022 Review and Outlook

Mining companies outperform broader market.

During the first quarter, mining companies (as measured by the XME) appreciated 36.9% compared to a loss of 4.9% for the S&P 500 index. The VanEck Vectors Gold Miners (GDX) and Junior Gold Miners (GDXJ) ETFs were up 19.7% and 11.8%, respectively. Gold, silver, copper, and zinc futures prices rose 6.5%, 7.5%, 6.7%, and 20.9%, respectively, while lead was down 0.3%. The war in Ukraine has constrained supplies of commodities, everything from fertilizer, grain, oil, natural gas, and metals, and magnified inflationary trends. How long this will continue is uncertain.

Outlook for precious metals.

The U.S. Dollar Index rose 2.4% during the first quarter, while the yield on a 10-year treasury note rose to 2.33% from 1.51% at year-end 2020. With the U.S. Federal Reserve signaling more aggressive action to combat inflation, further gains for gold may be challenged for the remainder of the year in the face of higher rates and a stronger dollar. However, with consumer and core inflation at 7.9% and 6.4% through February, respectively, real interest rates remain negative and enhance gold’s appeal as a store of value. Moreover, precious metals may be viewed as insurance against expected market volatility and economic uncertainty.

Risk of slowing economic growth may impact industrial metals.

With the Federal Reserve behind the curve on inflation and an unanticipated war stressing commodity markets, choking back demand and growth may be an obvious choice to combat inflation and supply shortages. A key worry is the risk of recession in the U.S. and abroad versus a softer landing. However, improving supply chains, inventory re-stocking, and greater capital spending could be supportive of pricing, and we believe the long-term investment case for owning industrial metals mining companies remains favorable. However, industrial metals may also be challenged to post further gains into the latter part of the year.

Putting it all together.

While much uncertainty remains, including the trajectory of the war in Ukraine, the U.S. Federal Reserve will likely achieve its goal of tamping down inflation. Despite a cautious near-term outlook, precious and industrial metals prices could hold up relatively well despite near-term headwinds. As a means of portfolio diversification, exposure to the mining sector is beneficial and investors may want to consider junior mining companies due to more attractive valuations relative to larger cap peers and the potential for increased M&A and industry consolidation.

Source: Capital IQ as of 03/31/2022

Gold Mining – Comparable Tables 

Source: Capital IQ as of 03/31/2022

Gold Mining – LTM Equity Performance 

Source: Capital IQ as of 03/31/2022

Silver Mining – Comparable Tables 

Source: Capital IQ as of 03/31/2022

Silver Mining – LTM Equity Performance 

Source: Capital IQ as of 03/31/2022

Gold & Silver – LTM Global M&A Activity 

Source: Capital IQ as of 03/31/2022

Diversified Mining – Comparable Tables 

Source: Capital IQ as of 03/31/2022

Diversified Mining – LTM Equity Performance 

Source: Capital IQ as of 03/31/2022

Diversified Mining – LTM Global M&A Activity 

Source: Capital IQ as of 03/31/2022

LTM Mining Industry M&A Summary 

Source: Capital IQ as of 03/31/2022

NOBLE QUARTERLY HIGHLIGHTS

Cypress Development Corp. (TSXV:CYP, OCTQB:CYDVF)

Industry: Metals and Mining – Diversified Metals and Mining

Cypress Development Corp. is a Canadian based advanced stage lithium exploration company, focused on developing its 100%-owned Clayton Valley Lithium Project in Nevada, USA. Work completed by Cypress led to the discovery of a world-class resource of lithium-bearing claystone adjacent to the Albemarle Silver Peak mine, North America’s only lithium brine operation. Cypress is advancing its Clayton Valley Lithium Project in Nevada towards the production of high-purity lithium hydroxide suitable for tier one battery usage.

1st Quarter News Highlight:

February 4, 2022: Cypress Development Completes Over-Subscribed $18.1 million bought deal financing. Pursuant to the Offering, the Company issued a total of 9,058,000 units of the Company (“Units”) at a price of $2.00 per Unit and 142,000 Warrants (as defined below) at a price of $0.1598 per Warrant, for aggregate gross proceeds of $18,138,720. Each Warrant entitles the holder to acquire one common share of the Company at a price of $2.65 with a Warrant expiry date of February 4, 2024. The net proceeds from the Offering are expected to be used by the Company to fund ongoing work, development and permitting activities at its Clayton Valley Lithium Project in Nevada and for working capital and general corporate purposes.

Maple Gold Mines Ltd. (TSXV:MGM, OCTQB:MGMLF)

Industry: Metals and Mining – Gold

Maple Gold Mines Ltd. is a Canadian advanced exploration company in a 50/50 joint venture with Agnico Eagle Mines Limited to jointly advance the district-scale Douay and Joutel gold projects located in Quebec’s prolific Abitibi Greenstone Gold Belt. The projects benefit from exceptional infrastructure access and boast ~400 km2 of highly prospective ground including an established gold resource at Douay (SLR 2022) that holds significant expansion potential as well as the past-producing Eagle, Telbel and Eagle West mines at Joutel.

1st Quarter News Highlight:

March 17, 2022: The Company reported a substantial resource increase in the Douay property after an updated Mineral Resource Estimate performed during the first quarter. Indicated resources increased by 21% to 511,000 OZ AU, and inferred resources increased by 7% to 2,525,000 OZ AU. Matthew Hornor – President and CEO – commented: “Looking ahead, the Company is targeting larger step-out and deeper drilling along the full extent of the Douay resource area.”

Allegiant Gold Ltd. (OTCQX:AUXXF)

Industry: Metals and Mining – Gold

Allegiant owns 100% of ten highly-prospective gold projects in the United States, seven of which are in the mining-friendly jurisdiction of Nevada. Three of Allegiant’s projects are farmed-out, providing for cost reductions and cash-flow. Allegiant’s flagship, district-scale Eastside project hosts a large and expanding gold resource and is in an area of excellent infrastructure.

1st Quarter News Highlight:

March 17. 2022: The company announced the completion of its previously announced $4,014,414 financing and strategic investment by Kinross Gold Corporation for the exploration and development of the Eastside property in Nevada. As a result, Kinross now owns 9.9% of the issued and outstanding shares of Allegiant. The strategic investment by Kinross calls for the formation of a four-person Technical Advisory Committee comprised of two members from each company. The Technical Advisory Committee will provide advice and guidance on the upcoming core-drilling program at the HGZ within the Original Pit Zone at Eastside.

Source: Company Press Releases

DOWNLOAD THE FULL REPORT (PDF)

Noble Capital Markets Metals & Mining Newsletter Q1 2022

This newsletter was prepared and provided by Noble Capital Markets, Inc. For any questions and/or requests regarding this newsletter, please contact >Francisco Penafiel

DISCLAIMER

All statements or opinions contained herein that include the words “ we”,“ or “ are solely the responsibility of NOBLE Capital Markets, Inc and do not necessarily reflect statements or opinions expressed by any person or party affiliated with companies mentioned in this report Any opinions expressed herein are subject to change without notice All information provided herein is based on public and non public information believed to be accurate and reliable, but is not necessarily complete and cannot be guaranteed No judgment is hereby expressed or should be implied as to the suitability of any security described herein for any specific investor or any specific investment portfolio The decision to undertake any investment regarding the security mentioned herein should be made by each reader of this publication based on their own appraisal of the implications and risks of such decision This publication is intended for information purposes only and shall not constitute an offer to buy/ sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice Past performance is not indicative of future results.

Please refer to the above PDF for a complete list of disclaimers pertaining to this newsletter

Rumors of Fossil Fuels Death are Quite Premature


Image Credit: Bruce Fingerhood (Flickr)


While Many Investors are Shunning Coal as Yesterday’s Energy, the Industry May Have Just Entered a Supercycle

 

Investor conferences are full of companies helping investors better understand newer industries and then showcasing individual company business models and “value propositions.”  The annual NobleCon Investor conference showcases growth companies, arguably, better than any other event. While attending this year’s NobleCon, I sat in on a presentation by a company up 277% YoY and trending higher. The industry dates back to the 1700s in the US, and the product had recently been rumored to have outlived its usefulness. Yet scheduled in between small companies doing groundbreaking work in life sciences, electronic games, and high-tech trading systems was a company still breaking ground mining coal and extracting other fossil fuels. The company’s stock market returns are staggering, and the presentation (video
available here
) pointed to a positive outlook both for the company and the industry.


Image: Brian Cantrell, SVP and CFO of Alliance Resource Partners, discusses the future of his company at NobleCon18


About the Company and Fossil Fuels

Alliance Resource Partners (ticker: ARLP), is the second-largest coal producer in the eastern US. Alliance markets its coal production to major domestic and international utilities and industrial users. The company derives income from coal production and oil & gas mineral interests located in seven strategic mining bases across the eastern states. The company has a market cap of $1,953m and is trading at $15.36 (April 26) up from $5.48 one year earlier.

Brian Cantrell, the CFO of ARLP, led the investor-facing presentation that highlighted his company’s challenges through the pandemic and the current stature and strength since mid-2021. The CFO explained that the price for natural gas began to rise last year, which fueled demand for less expensive coal. This was followed by what he called the “unfortunate situation in Ukraine” which is benefitting the price of fossil fuels as international consumers are weaning themselves off Russian natural gas. It’s far cheaper now to power from coal than natural gas.

Feeding into this perfect storm for coal prices has been an unwillingness of capital to support any fossil fuel projects. This has slowed any recovery from the supply shock. Also feeding into longer-term elevated prices is that fuel stockpiles had been very low where needed. There was a presumption that production could automatically respond, Cantrell explained that while it varies by unit and utility, end-users like to have 45 days’ worth on hand as a buffer to manage demand.

Today the fossil fuel industry has its own version of supply chain problems as fuel buyers are having difficulty finding producers with enough capacity to refill their buffer, which has in many cases been critically shortened. Internationally the US has been the swing producer, filling gaps outside of North America when needed with short-term, vessel-by-vessel, or quarter-by-quarter contracts. This demand has stressed the capacity to produce. Alliance has introduced artificial intelligence into its operation to create efficiencies for mining and extraction and to improve safety and productivity.

The
Future of the Industry

During the Alliance Resource Partners presentation, it was asked if current supply/demand fundamentals, because of lack of capital support, are forcing companies to live within their cash flows? Increased output may not come quick within the industry as it’s not in a position to leverage up while prices are under upward pressure; the presenter pointed out that ESG pressures are real. This could place this sector within a new supercycle.

Take-Away

Investment ideas are not limited to whatever the latest invention is. Often there is so much buzz around the “hot” “disruptive” industry that other opportunities have the potential to be overlooked.

Coal producers may be worth paying attention to for some time. Alliance’s CFO mentioned that he believes coal will continue to be an important part of power generation in the US and internationally.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading



No Punches Pulled at NobleCon18 Panel Discussion



EV Inflation Outpacing Traditional Cars





Evaluating Gold Royalty Companies to Gain Exposure to Precious Metals



Metals & Mining First Quarter 2022 Review and Outlook

 

Sources

NobleCon18 Investor Presentation,
Alliance Resources (Replay Video)

https://www.arlp.com/investor-relations/investor-overview/corporate-profile/default.aspx

 

Stay up to date. Follow us:

 

Release – Voyager Digital Kicks Off Its New Crypto For All Campaign And Announces Key Business Milestones

 



Voyager Digital Kicks Off Its New “Crypto For All” Campaign And Announces Key Business Milestones

Research, News, and Market Data on Voyager Digital

 

Company has completed over 36 million consumer crypto transactions and taken in over $5.5 billion in total net new retail deposits since inception as of March 31, 2022

NEW YORKApril 25, 2022 /PRNewswire/ – Voyager Digital Ltd. (“Voyager” or the “Company”) (TSX: VOYG) (OTCQX: VYGVF) (FRA: UCD2), one of the fastest-growing consumer cryptocurrency platforms in the United States, today announced it launched its new “Crypto for All” campaign across media channels in the U.S.

The Company also announced reaching several key business milestones. It has completed over 36 million consumer crypto transactions since it first released its mobile app, over 80% of which have been completed in the past 12 months. In addition, the Company shared that it has exceeded over $5.5 billion in net new retail deposits since inception, with 73% of those new deposits completed in the 12 months ended March 31, 2022.

“Voyager is, first and foremost, focused on advocating for the crypto consumer. And even amid this inevitable period of regulatory uncertainty, we have not seen any material impacts on our business. We continue to see healthy growth in net new dollar and crypto deposits as well as increased customer engagement on the platform. It is an exciting time for crypto, and I couldn’t be more optimistic about our company and our future,” said Steve Ehrlich, Voyager’s CEO and co-founder.

Voyager’s “Crypto for All” campaign brings more humanity and accessibility to the world of crypto. The new campaign features Voyager customers from a variety of backgrounds sharing their thoughts and experiences with crypto and Voyager–highlighting transparency, inclusivity, freedom, and opportunity. The campaign is currently running across a wide range of digital channels in the United States. A video sample of the campaign can be viewed here.

Voyager will also participate in several upcoming investor and crypto-industry conferences throughout fiscal Q4 2022, these include:

  • SALT Crypto Bahamas, Thursday, April 28, 2022 
  • Blooomberg: Investing in Tomorrow, Wednesday, May 11, 2022 
  • OTC Crypto Conference, Thursday, May 19, 2022 
  • H.C. Wainwright Global Investment Conference, Tuesday, May 24, 2022 
  • B. Riley Institutional Investor Conference, Wednesday, May 25, 2022

For more information about investor events Voyager will be participating in, please visit www.investvoyager.com/investorrelations/events.

Voyager is scheduled to announce the results of its fiscal 2022 third quarter ending March 31st on Monday, May 16th. To register for the call, go to the earnings event webcast link on the Voyager events page.

About Voyager Digital Ltd.

Voyager Digital Ltd.’s (TSX: VOYG) (OTCQX: VYGVF) (FRA: UCD2) US subsidiary, Voyager Digital, LLC, is a fast-growing cryptocurrency platform in the United States founded in 2018 to bring choice, transparency, and cost-efficiency to the marketplace. Voyager offers a secure way to trade over 100 different crypto assets using its easy-to-use mobile application. Through its subsidiary Coinify ApS, Voyager provides crypto payment solutions for both consumers and merchants around the globe. To learn more about the company, please visit https://www.investvoyager.comwww.investvoyager.com.

The TSX has not approved or disapproved of the information contained herein.

Press Contacts

Voyager Digital, Ltd. 
Voyager Public Relations Team
pr@investvoyager.com

SOURCE Voyager Digital (Canada) Ltd.

Release – Tonix Pharmaceuticals to Present at B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference



Tonix Pharmaceuticals to Present at B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference

Research, News, and Market Data on Tonix Pharmaceuticals

 

CHATHAM, N.J., April 25, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, President and Chief Executive Officer of Tonix Pharmaceuticals, will present at B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference on Wednesday, April 27, 2022, at 1:00 p.m.ET.

A webcast of the presentation will be available under the IR Events tab of the Tonix website at www.tonixpharma.com.

About Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s rare disease portfolio includes TNX-29002 for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox called TNX-8013, next-generation vaccines to prevent COVID-19, and an antiviral to treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-18504, which are live virus vaccines based on Tonix’s recombinant pox vaccine (RPV) platform. TNX-35005 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development. TNX-102 SL6, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL, is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022. Finally, TNX-13007 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA.

1TNX-1500 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.
2TNX-2900 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.
3TNX-801 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.
4TNX-1840 and TNX-1850 are investigational new biologics at the pre-IND stage of development and have not been approved for any indication. 
5TNX-3500 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.
6TNX-102 SL is an investigational new drug and has not been approved for any indication.
7TNX-1300 is an investigational new biologic and has not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Olipriya Das, Ph.D. (media)
Russo Partners
Olipriya.Das@russopartnersllc.com
(646) 942-5588

Peter Vozzo (investors)
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

Source: Tonix Pharmaceuticals Holding Corp.

Release – RCI to Hold 2Q22 Earnings Call on Twitter Spaces



RCI to Hold 2Q22 Earnings Call on Twitter Spaces

Research, News, and Market Data on RCI Hospitality Holdings

Will Be First Company to Use Twitter Spaces for
Earnings Call

HOUSTON – April 25, 2022 – RCI Hospitality Holdings, Inc. (Nasdaq: RICK) announced plans to be the first company to use Twitter’s Spaces platform for its 2Q22 earnings conference call. RCI now becomes the first mover to embrace a new medium of corporate communication that the company hopes will increase informational access to current and prospective shareholders.

Eric Langan, President and CEO of RCI Hospitality
Holdings, Inc., said,
“Twitter is the social media town square for people, news, and ideas. As we continue to build off our industry leadership, it’s only natural that we are the first company to use Twitter’s Spaces in this way.”

RCI’s use of Twitter Spaces is being facilitated by Litquidity
Media, Inc.
, a digital media company reaching over a million investors and finance leaders each month with its portfolio of social media brands and coverage of Wall Street culture.

The call will be held Monday or Tuesday, May 9 or 10, 2022, at 4:30 PM ET. The company plans to file a 10-Q for its fiscal 2022 second quarter ended March 31, 2022, after the market closes the day of the call. RCI will announce the call date and more Twitter Spaces information when it is finalized.

After the call ends, investors can spend the evening meeting management at Tootsie’s Cabaret Miami, RCI’s 74,000 square foot mega club.

Twitter Spaces Details

Telephone Details

  • Live Participant Phone: Toll Free 888-506-0062, International 973-528-0011, Passcode: 384318
  • Phone replay: Toll Free 877-481-4010, International 919-882-2331, Passcode: 45285

Slides & Webcast Details

Meet Management Details

  • Tootsie’s Cabaret Miami, 150 NW 183rd St., Miami, FL 33169
  • RSVP your contact information to gary.fishman@anreder.com

About RCI Hospitality Holdings, Inc. (Nasdaq: RICK) www.rcihospitality.com

With more than 50 units, RCI Hospitality Holdings, Inc., through its subsidiaries, is the country’s leading company in adult nightclubs and sports bars/restaurants. Clubs in New York City, Chicago, Dallas-Fort Worth, Houston, Miami, Minneapolis, Denver, St. Louis, Charlotte, Pittsburgh, Raleigh, Louisville, and other markets operate under brand names such as Rick’s Cabaret, XTC, Club Onyx, Vivid Cabaret, Jaguars Club, Tootsie’s Cabaret, and Scarlett’s Cabaret. Sports bars/restaurants operate under the brand name Bombshells Restaurant & Bar.

Forward-Looking Statements

This press release may contain forward-looking statements that involve a number of risks and uncertainties that could cause the company’s actual results to differ materially from those indicated, including, but not limited to, the risks and uncertainties associated with (i) operating and managing an adult business, (ii) the business climates in cities where it operates, (iii) the success or lack thereof in launching and building the company’s businesses, (iv) cyber security, (v) conditions relevant to real estate transactions, (vi) the impact of the COVID-19 pandemic, and (vii) numerous other factors such as laws governing the operation of adult entertainment businesses, competition and dependence on key personnel. For more detailed discussion of such factors and certain risks and uncertainties, see RCI’s annual report on Form 10-K for the year ended September 30, 2021, as well as its other filings with the U.S. Securities and Exchange Commission. The company has no obligation to update or revise the forward-looking statements to reflect the occurrence of future events or circumstances.

______________________

 

Gary M. Fishman

Anreder & Company

Office: 212-532-3232

Mobile: 917-566-9869

http://www.anreder.com

Release – Comstock Announces First Quarter 2022 Webcast



Comstock Announces First Quarter 2022 Webcast

Research, News, and Market Data on Comstock Mining

 

VIRGINIA CITY, NEVADA, APRIL 25, 2022 – Comstock Mining Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced that it will host a conference call on Tuesday, May 3, 2022, at 8:00 a.m. Pacific Daylight Time (11:00 a.m. Eastern Daylight Time) to report its First Quarter 2022 results and business updates. The webcast will include a moderated question and answer session after the Company’s prepared remarks.  Please click the link below to register in advance and please join the event at least 10 minutes prior to the scheduled start time.

Once registered, you will receive a confirmation email containing information about joining the Webcast.

May 3, 2022, 08:00 AM Pacific Daylight Time / 11:00 AM Eastern Daylight Time (US and Canada)

Topic: Comstock’s Q1 2022 Results and Business Update

Please click here to register in advance for this webcast.

About Comstock 

Comstock (NYSE: LODE) innovates technologies that enable systemic decarbonization and circularity by efficiently converting under-utilized wasted and other natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. To learn more, please visit www.comstock.inc.

Forward-Looking Statements

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements, but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future industry market conditions; future explorations or acquisitions; future changes in our exploration activities; future changes in our research and development; and future prices and sales of, and demand for, our products and services. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Neither this press release nor any related call or discussion constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund or any other issuer.

  Contact information:    
Comstock Mining Inc.
P.O. Box 1118
Virginia City, NV 89440
ComstockMining.com
Corrado De Gasperis
Executive Chairman & CEO
Tel (775) 847-4755
degasperis@comstockmining.com
Zach Spencer
Director of External Relations
Tel (775) 847-5272 Ext.151
questions@comstockmining.com

Release – Schwazze Announces Virtual Town Hall Meeting



Schwazze Announces Virtual Town Hall Meeting

Research, News, and Market Data on Schwazze

 

DENVER, Colo.April 25, 2022 /CNW/ – Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) (“Schwazze” or the “Company”), is pleased to announce that Justin Dye, Chairman & CEO will present to investors in a live VID Forum Town Hall on Tuesday, April 26, 2022, at 11:00 am EST. Management will field Q&A from investors and interested parties after their presentation. Please sign up here to register.

The Webinar will be interactive and will be hosted by VID Conferences.  All stakeholders and interested investors are welcome to tune in and participate with questions. The playback will then be available on the Company’s website.

About Schwazze
Schwazze (OTCQX: SHWZ) (NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices. Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc.

Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth.

Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “plan,” “will,” “may,”, “predicts,” or similar words. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; (v) difficulties in securing regulatory approval to market our products and product candidates; (vi) our ability to successfully execute our growth strategy in Colorado and outside the state, (vii) our ability to consummate the acquisition described in this press release or to identify and consummate future acquisitions that meet our criteria, (viii) our ability to successfully integrate acquired businesses and realize synergies therefrom, (ix) the ongoing COVID-19 pandemic, * the timing and extent of governmental stimulus programs, (xi) the uncertainty in the application of federal, state and local laws to our business, and any changes in such laws, and * out ability to satisfy the closing conditions for the private finding described in this press release. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/schwazze-announces-virtual-town-hall-meeting-301531590.html

SOURCE Medicine Man Technologies, Inc.

Release – Ocugen Inc. Announces Positive DSMB Recommendation For OCU400-101 Clinical Trial



Ocugen, Inc. Announces Positive DSMB Recommendation For OCU400-101 Clinical Trial

Research, News, and Market Data on Ocugen

 

PHASE 1/2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU400 MODIFIER GENE THERAPY CANDIDATE TO TREAT RETINITIS PIGMENTOSA ASSOCIATED WITH NR2E3 AND RHO MUTATIONS

MALVERN, Pa., April 25, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, announced today that the independent Data and Safety Monitoring Board (DSMB) for its Phase 1/2 clinical trial of OCU400, the Company’s flagship modifier gene therapy candidate for the treatment of Retinitis Pigmentosa (RP), reviewed safety data based on dosing to date and recommended that the study proceed with enrolling additional subjects.

The OCU400-101 clinical study to assess the safety and efficacy of modifier gene therapy candidate OCU400 for RP resulting from mutations in the nuclear receptor subfamily 2 group E member 3 (NR2E3) and Rhodopsin (RHO) genes recently dosed its first patient. The DSMB recommended that the Company continue enrolling the remaining study subjects in this current cohort at the target dose level.

Ocugen’s modifier gene therapy platform targets nuclear hormone receptors (NHRs) that regulate multiple functions within the retina, giving it the potential to address many different gene mutations – and in turn, multiple retinal diseases – with a single product. Traditional gene therapy, which transfers a functional version of a non-functional gene into target cells, addresses only one individual gene mutation at a time.

“It’s a positive first step that the DSMB review of the current OCU400-101 study results identified no serious adverse events and recommended that the study proceed with enrollment,” said Mark Pennesi, MD, PhD, Professor of Ophthalmology and Chief of the Paul H. Casey Ophthalmic Genetics Division, Oregon Health & Science University, and member of Ocugen’s Retina Scientific Advisory Board. “We’re looking forward to understanding how this modifier gene therapy platform could treat inherited retinal degeneration, potentially bringing an option to people affected with this disease.”

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions, including with respect to our Phase 1/2 trial included in our Investigational New Drug application to the U.S. Food and Drug Administration (FDA) for OCU400, which is actively enrolling patients following review of preliminary safety data by the independent Data and Safety Monitory Board. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary and interim data, including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that the results of in-vitro studies will not be duplicated in human clinical trials; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; and the risk that the Orphan Drug Designations from the FDA and broad Orphan Medicinal Product Designation from the European Commission for OCU400 may not result in a faster approval timeline for OCU400 or increase the likelihood of any such approvals These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:
Ken Inchausti
Head, Investor Relations & Communications
ken.inchausti@ocugen.com

Please submit investor-related inquiries to: IR@ocugen.com

Release – Salem Media Announces the Appointment of Scott Furrow at its 99.5 KKLA Station



Salem Media Announces the Appointment of Scott Furrow at its 99.5 KKLA Station

Research, News, and Market Data on Salem Media

 

IRVING, Texas–(BUSINESS WIRE)– Salem Media Group, Inc. (NASDAQ: SALM) announced today that Scott Furrow has been appointed host of ‘SoCal Live’, weekday afternoons 3-5pm on 99.5 FM KKLA.

Scott Furrow
Scott Furrow (Photo: Business Wire)

Born and raised in Southern California, Scott graduated from UC Riverside, earning a bachelor’s degree in history/law and society. Scott’s career has included roles in politics, government, media relations, as well as the corporate marketplace. He received his Master of Divinity degree from Bethel Theological Seminary in San Diego. A pastor for 25 years, Scott served as Senior Pastor of the First Baptist Church of San Diego for the past 18 years.

99.5 KKLA Director of Programming, Rodney Miller commented, “Today’s announcement comes on the heels of an eight-month nationwide search which included fill-in SoCal LIVE guest hosts Bob Lepine, Pastor Dudley Rutherford, and New Life Live’s Steve Arterburn. We are grateful and appreciative to everyone who stepped in and gave so much of their time and talent during this search.”

Miller added, “I was extremely impressed with Scott Furrow’s decision two years ago to not only serve as Senior Pastor, but also host a daily radio program on sister station KPRZ in San Diego. Scott left his sermon notes at the Church and instead brought in the top news stories discussing them from a spiritual and values perspective. On ‘SoCal Live’, Scott will have two hours each weekday to bring hope and encourage our listeners to be salt and light in today’s rapidly changing culture.”

According to Salem Los Angeles Vice President/General Manager Terry Fahy, “Scott combines a quick wit, theological knowledge and wisdom, a strong grasp of the news, and empathy for issues facing our listeners. It’s a winning combination for talk radio in Southern California.”

Scott Furrow commented, “As a pastor, my passion and my calling has been encouraging people to grow in their faith and to be more Kingdom-minded in everyday life. Hosting the ‘SoCal LIVE’ weekday program on 99.5 FM KKLA will enable me to do that on a much larger scale. I can hardly wait!”

Scott Furrow will also be heard on FM 106.1/AM 1210 KPRZ weekday afternoons 3-5pm.

ABOUT SALEM MEDIA GROUP:

Salem Media Group is America’s leading multimedia company specializing in Christian and conservative content, with media properties comprising radio, digital media and book and newsletter publishing. Each day Salem serves a loyal and dedicated audience of listeners and readers numbering in the millions nationally. With its unique programming focus, Salem provides compelling content, fresh commentary and relevant information from some of the most respected figures across the Christian and conservative media landscape. Learn more about Salem Media Group, Inc. at www.salemmedia.comFacebook and Twitter.

Evan D. Masyr
Executive Vice President and Chief Financial Officer
(805) 384-4512
evan@salemmedia.com

Source: Salem Media Group, Inc.

The Trend in Currency Reserve Status and Market Impact


Image Credit: Can Pac Swire (Flickr)


Challenges to the US Dollar as a Reserve Currency and Market Impact

 

The percentage of US dollars used by foreign central banks as their reserve currency, has fallen dramatically in the past seven years. During this same period, a greater share of global reserves are being held in Chinese yuan. Could this shift impact US investments, including stocks and interest-bearing securities? Will US living standards suffer?

When any reserve currency, including gold, the Euro, the yuan and others, experiences increased demand, its value is enhanced. Fading demand has the impact of decreasing value which pushes upward on inflation for goods transacted in that currency. A weakening currency also demands higher interest rates to attract use. Valuations across all dollar-denominated markets may get dragged down with a declining dollar as well.

 

Background

The United States dollar has been the world’s primary reserve currency for over 60 years. Before the early 1970s, the dollar had been pegged to gold and most other currencies were then valued off the dollar. Since dollars are easier to work with than gold, greenbacks were used as the main intervention currency for monetary policy adjustments outside (and inside) of the US.

The establishment of the European monetary union and the euro in 1999 led to predictions of the dollar weakening. These fears were not realized. The use of the dollar as the primary reserve currency is based on the US maintaining a position as the world’s dominant economy. US dollars did not reach the position of reserve currency by world leaders somehow meeting and deciding to use dollars. Instead, it was based on trust and size of the US economy and debt market.

It does however make international transactions easier if currencies are priced to one currency.


Recent Trend

Using measurements from just before the Russian sanctions from the West, the percentage of dollars used as a currency dropped below 59% (Q4 2021).  This is down from 62% at the beginning of 2020, and 65% five years earlier in 2015. The trend toward using other currencies has recently accelerated.

The declining use of the dollar is even more dramatic when currency values are factored in. The recent strengthening of the dollar is masking a steeper drop in its “per unit” reserve status; the increase in momentum may have begun in 2018 when the US imposed tariffs on specific goods from China and a few other nations.

The euro is the second most widely-held reserve currency. It had experienced a net reduction over the last decade, but so far this decade has ticked higher. The trend seems to show that central banks are diversifying their reserve holdings.  It would not be surprising if future data shows that the war in Europe has caused a lower level of use of euros as reserves.

Rising bond yields are likely to drive flows to dollars as long as competing currency, real yields (after inflation) aren’t rising more rapidly.

Very recently the Yuan has lost value as Beijing has re-imposed strict lockdowns related to coronavirus activity.  Coupled with rising rates in the US and Europe, the Yuan should be under downward pressure.


Impact on Markets

Ordinarily, a softening yuan against US dollars would add to the two countries’ trade imbalances. Strong dollars make imports cheap. However, if production does not keep up with demand because of new lockdowns, the Chinese may not benefit from increased exports.

Inflation would be dampened somewhat on goods produced in China, but again if there is only a modest increase in imported goods from the US the inflation numbers reported will be barely impacted.

Strengthening dollars drive currency into US markets and could help support price levels during a period, like now, when there is a bearish tone due to a more hawkish monetary policy.


Take-Away

The US economy is experiencing its challenges for many different reasons. So are the other economies of the world. For this reason, central banks are diversifying. However, the US dollar is still considered to be the “risk-free” exchange medium against which others are measured. The size and scope of the US economy is likely to help the greenback retain its position, even as outside central banks decide to spread their risk around more than they have in the past.

 

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading



Panelists Pulled No Punches at NobleCon18 Discussing ESG, Politics, Inflation, and War



The Risky Position Elon Musk is Placing Himself In





Evaluating Gold Royalty Companies to Gain Exposure to Precious Metals



How did the Stock Market Perform Under Each President?


Sources

https://data.imf.org/?sk=E6A5F467-C14B-4AA8-9F6D-5A09EC4E62A4

https://www.chinabankingnews.com/2022/04/25/chinese-renminbi-rises-as-share-of-global-reserves-as-greenback-drops-to-record-low/

https://www.bis.org/publ/qtrpdf/r_qt1812b.pdf

 

Stay up to date. Follow us:

 

Release – Lineage Announces A Fifth Cell Therapy Program Allogeneic Photoreceptor Transplants

 



Lineage Announces A Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants For The Treatment Of Diseases Which May Lead To Blindness

Research, News, and Market Data on Lineage Cell Therapeutics

 

Dynamic Culturing Process Developed by Lineage Offers Path to Clinical- and Industrial-Scale Production of Photoreceptors

CARLSBAD, Calif.–(BUSINESS WIRE)–Apr. 25, 2022– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced a new cell therapy development program: photoreceptor neural cell (PNC) transplants for the treatment of vision loss due to photoreceptor dysfunction or damage. Similar to the company’s recently announced pipeline expansion into auditory neurons for the treatment of hearing loss, Lineage has filed for intellectual property protection covering the composition and methods for generating PNCs. Based on recent in vivo data generated using the company’s PNCs, these cells may be capable of forming reconstructed retina with high survivability and neural connectivity to surrounding functional layers. Notably, Lineage has demonstrated feasibility which could support a large-scale method for producing both types of photoreceptors, known as rods and cones.

“It is natural that, on the heels of the announcement of our alliance with Roche and 
Genentech for our RPE cell therapy, a deal worth up to 
$670 million dollars plus double-digit royalties if certain development, approval, and sales milestones are achieved and other conditions are met, that we also would pursue treatments for vision loss through the other major cell type of the retina, the photoreceptors,” stated  Brian Culley, Lineage’s CEO. “Our fundamental technology and accumulated know-how give us the opportunity to make many different cell types, and we have demonstrated our ability to create new programs rapidly and efficiently in two distinct areas, expanding our cell therapy pipeline to five separate preclinical and clinical programs, while still maintaining what we believe is an appropriate and responsible rate of investment for a company of our size. This latest program is part of our long-term planning for clinical and commercial success and serves as another example of the capability of our technology platform. We believe our ability to, in just a matter of months, advance from a product concept to generating new intellectual property and manufacturing the desired cell types, is illustrative of the power and efficiency of our platform. We believe the combination of our capital discipline and current balance sheet will support multiple years of further progress, during which we anticipate reaching achievements with each of our clinical and preclinical programs.”

Dr.  Rami Skaliter, who leads the manufacturing function for Lineage, added, “I’m exceptionally proud of the team’s success at overcoming obstacles related to the limited scale of photoreceptor production. Building upon our experience with other cell lineages, we have developed intellectual property, and filed for patent protections, on a manufacturing process which is compatible with large-scale production of photoreceptors in a closed system, improvements which could enable industrial manufacturing. We believe this accomplishment will provide new opportunities for clinical, and ultimately commercial, production of photoreceptors in areas of large unmet need such as Retinitis Pigmentosa, Stargardt’s Macular Dystrophy, and retinal detachments, either independently or through strategic alliances.”

As part of a scientific collaboration with Professors  Benjamin Reubinoff, M.D., Ph.D. and  Eyal Banin, M.D., Ph.D., of the 
Hadassah-Hebrew University Medical Center, the differentiation of pluripotent cells into photoreceptors with clinically compatible characteristics was established utilizing a novel differentiation protocol which generated positive identity of key markers of both rods and cones photoreceptor populations. The data generated by the company further demonstrated that a single cell suspension of photoreceptor precursor cells has the potential to survive and mature post-transplantation in a rodent model of retinal degeneration.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include five allogeneic (“off-the-shelf”) product candidates: (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being developed under a worldwide collaboration with Roche and
Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy, and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit www.lineagecell.com or follow the company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “aim,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to (i) the potential amount of payments to Lineage under the alliance with 
Hoffman-La Roche Ltd. (“Roche”) and 
Genentech, Inc., (ii) the potential for new opportunities for clinical, and ultimately commercial, production of photoreceptors in areas of large unmet need, (iii) Lineage’s position to become a leader in the emerging field of regenerative medicine and anti-aging technology, and (iv) future areas of potential treatment using PNC transplant. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the risk that competing alternative therapies may adversely impact the commercial potential of OpRegen, which could materially adversely affect the payments payable to Lineage under the Roche/
Genentech collaboration and license agreement, the risk that Roche/
Genentech may not be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction; the risk that Lineage might not succeed in developing products and technologies that are useful in medicine and demonstrate the requisite safety and efficacy to achieve regulatory approval in accordance with its projected timing, or at all; the risk that Lineage’s intellectual property may be insufficient to protect its assets; risks and uncertainties inherent in Lineage’s business and other risks discussed in Lineage’s filings with the 
Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the 
SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the 
SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963

Solebury Trout IR
Mike Biega
(Mbiega@soleburytrout.com)
(617) 221-9660

Russo Partners – Media Relations
Nic Johnson or  David Schull
Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com
(212) 845-4242

Source: 
Lineage Cell Therapeutics, Inc.

Release – Kratos Awarded Contract to Deliver OneWeb Spectrum Monitoring System for its LEO Satellite Constellation



Kratos Awarded Contract to Deliver OneWeb Spectrum Monitoring System for its LEO Satellite Constellation

Research, News, and Market Data on Kratos Defense & Security Solutions

 

SAN DIEGO
April 25, 2022 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that it has been awarded a contract to deliver an advanced spectrum monitoring system for OneWeb to monitor, analyze and review the utilized spectrum to support high quality of service for its fleet of Low Earth Orbit (LEO) constellations.

The system will monitor the spectrum used between its global network of Satellite Network Portal (SNP) gateways and its constellation of LEO satellites. The OneWeb Spectrum Monitoring System (OSMS) will help staff monitor, manage and analyze this spectrum, the radio frequencies that satellite signals travel over.

“With our fleet of LEO satellites that will deliver on our mission to provide space connectivity around the world, it is critical for us to monitor and manage the RF spectrum to ensure that we are delivering on our service performance targets,” stated  David Price, Vice President, Access Layer Program at OneWeb. “We are working with Kratos, experts in RF monitoring, measurement and analysis to design, build and integrate the system into our ground operations.”

The OSMS will incorporate Kratos’ industry-leading, integrated spectrum monitoring capabilities to enable real-time management of Radio Frequency (RF) usage and to monitor compliance with frequency transmission regulations. As part of the contract, Kratos is responsible for designing, developing, and installing the OSMS and integrating the system with OneWeb’s ground segment.

At the heart of the OSMS LEO monitoring solution, Kratos will deploy a big data processing, storage and analytics platform for satellite operations. The system will retrieve, store, and access the spectrum traces captured at each antenna during a satellite pass. The RF data across all gateway sites will be consolidated through the OSMS to enable OneWeb’s Network Operations staff to centrally monitor, review,s and analyze the spectrum.

“The OSMS is being built to address the need to monitor very fast-moving LEO satellites and scale to the needs of OneWeb’s fleet of satellites. The Kratos technology used in the OSMS can retrieve, process, and store the high volume of data at almost one gigabit per second on the ground,” explained  Bruno Dupas, President of 
Kratos Communications in 
France. “Kratos and OneWeb are working together to successfully deploy the OSMS, one of the most advanced spectrum monitoring systems for LEO constellations in the industry.”

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 26, 2021, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
investor@kratosdefense.com 

Source: Kratos Defense & Security Solutions, Inc.

Financial Protection Bureau Has New Supervisory Powers



CFPB Invokes Dormant Authority to Examine Nonbank Companies Posing Risks to Consumers

 

WASHINGTON, D.C. – The Consumer Financial Protection Bureau (CFPB) announced that it is invoking a largely unused legal provision to examine nonbank financial companies that pose risks to consumers. The CFPB believes that utilizing this dormant authority will help protect consumers and level the playing field between banks and nonbanks. The CFPB is also seeking public comments on a procedural rule to make this process more transparent.

“Given the rapid growth of consumer offerings by nonbanks, the CFPB is now utilizing a dormant authority to hold nonbanks to the same standards that banks are held to,” said CFPB Director Rohit Chopra. “This authority gives us critical agility to move as quickly as the market, allowing us to conduct examinations of financial companies posing risks to consumers and stop harm before it spreads.”

Under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the CFPB has authority to use traditional law enforcement to stop companies from engaging in conduct that pose risk to consumers; this can involve adversarial litigation. However, the law also gives the CFPB authority to conduct supervisory examinations to review the books and records of regulated entities. CFPB examiners typically provide a report to entities with problems that need to be addressed, and responsible institutions typically take prompt corrective action.

Nonbank Supervision

For decades before the Dodd-Frank Act, only banks and credit unions were subject to federal supervision. But after the 2008 financial crisis in which nonbank companies played a pivotal role, Congress tasked the CFPB with supervising certain nonbanks, in addition to large depository institutions with more than $10 billion in assets, and their service providers. Nonbanks do not have a bank, thrift, or credit union charter; many today operate nationally and brand themselves as “fintechs.”

Congress authorized several categories of entities subject to CFPB’s nonbank supervision program. First and foremost, all nonbank entities in the mortgage, private student loan, and payday loan industries, regardless of size. Another category of supervised entities includes what the law calls “larger participants” in other nonbank markets for consumer financial products and services. The CFPB conducted rulemakings to define thresholds for entities subject to supervision in the markets of consumer reporting, debt collection, student loan servicing, international remittances, and auto loan servicing.

The third category of entities subject to the CFPB nonbank supervision are nonbanks whose activities the CFPB has reasonable cause to determine pose risks to consumers. This authority is not specific to any particular consumer financial product or service. While the CFPB did implement the provision through a procedural rule in 2013,  the agency has now begun to invoke this authority. This will allow the CFPB to be agile and supervise entities that may be fast-growing or are in markets outside the existing nonbank supervision program.

Such risky conduct may involve, for example, potentially unfair, deceptive, or abusive acts or practices, or other acts or practices that potentially violate federal consumer financial law. The CFPB may base such reasonable cause determinations on complaints collected by the CFPB, or on information from other sources, such as judicial opinions and administrative decisions. The CFPB may also learn of such risks through whistleblower complaints, state partners, federal partners, or news reports.

Transparency

The CFPB is also issuing a procedural rule today to increase the transparency of the risk-determination process. Unlike other provisions of law regarding nonbank supervision, entities subject to supervision based on risk are given notice and an opportunity to respond. In order to provide greater guidance to the marketplace on how the CFPB will make determinations, the CFPB is updating an aspect of its procedures for risk determinations to authorize the release of certain information about any final determinations made.  The company involved will have an opportunity to provide input to the CFPB on what information is released to the public.

 

Suggested Reading



Will Mortgage Forbearance Impact Other Markets? (April 2021)



How Much is a Trillion?

 

Sources

https://www.consumerfinance.gov/about-us/blog/introducing-our-new-bureau-seal/

https://www.consumerfinance.gov/

 

Stay up to date. Follow us: